INS NYC 2024 Program

Poster	Poster Session 02 Program Schedule 02/15/2024 08:00 am - 09:15 am Room: Majestic Complex (Posters 61-120) Poster Session 02: Aging \| MCI \| Neurodegenerative Disease - PART 1 Final Abstract #107 The Relationship between Subjective Cognitive Decline (SCD) and Objective Neuropsychological Testing at 3-6 Months, 12 Months, and 24 Months post-SAR-COV-2 Hospitalization Robbie Wong, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, United States Deepa Dongarwar, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States, Houston, United States Kendra Anderson, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States, Houston, United States Lucy Couture, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States, Houston, United States Ana Cahuiche, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States, Houston, United States Gabriela Colpo, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States, Houston, United States Louise McCullough, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States, Houston, United States Category: Medical/Neurological Disorders/Other (Adult) Keyword 1: memory complaints Keyword 2: cognitive functioning Keyword 3: mood disorders Objective: Objective: Subjective cognitive decline (SCD) is a growing public health concern and is recognized as an important risk factor for later progression to dementia. The long-term cognitive and neuropsychiatric impacts of SAR-COV-2 infection post-hospitalization have been hotly debated, with some studies finding poor/modest associations between SCD and cognitive impairment on objective testing. Other studies have posited neuropsychiatric symptoms (e.g., anxiety, depression, and trauma) are the primary culprits of SCD in SAR-COV-2. Yet, the vast majority of these studies have been cross-sectional and a minority of studies assess beyond 12-15 months post-hospitalization. This longitudinal study aimed to describe the relationship between baseline SCD and neuropsychological test performance after accounting for neuropsychiatric symptoms at 3-6, 12-, and 24 months post-hospitalization. Participants and Methods: Participants and Methods: Archival data was extracted from a SAR-COV-2 biorepository at a large academic medical center in southeast Texas. Study participants were patients hospitalized for SAR-COV-2 and followed at 3-6, 12-, and 24-months post-hospital discharge. SCD (yes/no), neuropsychological functioning (Braincheck) in the domains of memory, processing speed (oral and visuomotor), and executive functioning subtests, and symptoms of depression, anxiety, sleepiness, and post-traumatic stress disorder (PTSD) symptoms were assessed at all three time points. A bivariate analysis was conducted to assess the relationship between SCD and index scores of a computerized neuropsychological assessment. A generalized estimating equations model was utilized to examine the association between SCD and neuropsychological test performance (i.e., total and subtest scores), while controlling for the longitudinal follow-up time points and neuropsychiatric symptoms. Results: Forty participants (Aged 19-76; µ= 49.68 years) met the study inclusion criteria, with 55% identifying as female. The cohort was racially/ethnically diverse, with 55% of participants identifying as “White”, 17.5% as “Black”, 2.5% as “Asian,” 2.5% as “Hawaiian or Pacific Islander”, and 22.5% who identified differently from the available categories. At 24 months post-hospitalization, there was a significant relationship between SCD and cognition, specifically those with SCD at baseline tended to have lower immediate and delayed verbal recognition memory. There was no association between SCD and cognitive scores at 3-6 months or 12-month follow-up. After controlling for neuropsychiatric symptoms, the presence of SCD at baseline predicted worse global cognitive functioning at the 24-month follow-up, especially in the domains of visuomotor processing speed, immediate memory, and delayed recall. Conclusions: Conclusions: A relationship was observed between SCD and cognitive dysfunction at 24 months post-SAR-COV-2 hospitalization, most notably in verbal memory (immediate and delayed). The relationship between SCD and cognitive functioning remained significant for memory and processing speed at 24 months post-hospitalization, even after controlling for neuropsychiatric symptoms. Results suggest that neuropsychiatric symptoms may not fully account for SCD in SAR-COV-2 infection and SCD may be a valuable predictor of long-term objective cognitive decline related to SAR-COV-2 after 2+ years post-infection.

Poster

02/15/2024
08:00 am - 09:15 am
Room: Majestic Complex (Posters 61-120)

Poster Session 02: Aging | MCI | Neurodegenerative Disease - PART 1

Final Abstract #107

The Relationship between Subjective Cognitive Decline (SCD) and Objective Neuropsychological Testing at 3-6 Months, 12 Months, and 24 Months post-SAR-COV-2 Hospitalization

Robbie Wong, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, United States
Deepa Dongarwar, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States, Houston, United States
Kendra Anderson, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States, Houston, United States
Lucy Couture, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States, Houston, United States
Ana Cahuiche, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States, Houston, United States
Gabriela Colpo, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States, Houston, United States
Louise McCullough, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States, Houston, United States

Category: Medical/Neurological Disorders/Other (Adult)

Keyword 1: memory complaints
Keyword 2: cognitive functioning
Keyword 3: mood disorders

Objective:

Objective: Subjective cognitive decline (SCD) is a growing public health concern and is recognized as an important risk factor for later progression to dementia. The long-term cognitive and neuropsychiatric impacts of SAR-COV-2 infection post-hospitalization have been hotly debated, with some studies finding poor/modest associations between SCD and cognitive impairment on objective testing. Other studies have posited neuropsychiatric symptoms (e.g., anxiety, depression, and trauma) are the primary culprits of SCD in SAR-COV-2. Yet, the vast majority of these studies have been cross-sectional and a minority of studies assess beyond 12-15 months post-hospitalization. This longitudinal study aimed to describe the relationship between baseline SCD and neuropsychological test performance after accounting for neuropsychiatric symptoms at 3-6, 12-, and 24 months post-hospitalization.

Participants and Methods:

Participants and Methods: Archival data was extracted from a SAR-COV-2 biorepository at a large academic medical center in southeast Texas. Study participants were patients hospitalized for SAR-COV-2 and followed at 3-6, 12-, and 24-months post-hospital discharge. SCD (yes/no), neuropsychological functioning (Braincheck) in the domains of memory, processing speed (oral and visuomotor), and executive functioning subtests, and symptoms of depression, anxiety, sleepiness, and post-traumatic stress disorder (PTSD) symptoms were assessed at all three time points. A bivariate analysis was conducted to assess the relationship between SCD and index scores of a computerized neuropsychological assessment. A generalized estimating equations model was utilized to examine the association between SCD and neuropsychological test performance (i.e., total and subtest scores), while controlling for the longitudinal follow-up time points and neuropsychiatric symptoms.

Results:

Forty participants (Aged 19-76; µ= 49.68 years) met the study inclusion criteria, with 55% identifying as female. The cohort was racially/ethnically diverse, with 55% of participants identifying as “White”, 17.5% as “Black”, 2.5% as “Asian,” 2.5% as “Hawaiian or Pacific Islander”, and 22.5% who identified differently from the available categories. At 24 months post-hospitalization, there was a significant relationship between SCD and cognition, specifically those with SCD at baseline tended to have lower immediate and delayed verbal recognition memory. There was no association between SCD and cognitive scores at 3-6 months or 12-month follow-up. After controlling for neuropsychiatric symptoms, the presence of SCD at baseline predicted worse global cognitive functioning at the 24-month follow-up, especially in the domains of visuomotor processing speed, immediate memory, and delayed recall.

Conclusions:

Conclusions: A relationship was observed between SCD and cognitive dysfunction at 24 months post-SAR-COV-2 hospitalization, most notably in verbal memory (immediate and delayed). The relationship between SCD and cognitive functioning remained significant for memory and processing speed at 24 months post-hospitalization, even after controlling for neuropsychiatric symptoms. Results suggest that neuropsychiatric symptoms may not fully account for SCD in SAR-COV-2 infection and SCD may be a valuable predictor of long-term objective cognitive decline related to SAR-COV-2 after 2+ years post-infection.